Solabia Agrees to Acquire Mibelle Biochemistry, Seqens Botanical Actives & In-Vitro Diagnostics Activity, and Xebios Group
March 5, 2026
Solabia, a Paris-headquartered biotech platform focused on natural active ingredients and diagnostics solutions, has agreed to acquire three complementary businesses: Mibelle Biochemistry, Seqens’ Botanical Actives and In-Vitro Diagnostics activity, and Xebios Group. The acquisitions broaden Solabia’s capabilities in natural cosmetic actives and expand its microbiological diagnostics footprint in Europe as the company accelerates its international expansion strategy.
- Buyers
- Solabia
- Targets
- Mibelle Biochemistry, Seqens' Botanical Actives and In-Vitro Diagnostics activity, Xebios Group
- Platforms
- Solabia
- Industry
- Biotechnology
- Location
- France
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Astorg to Acquire Majority Stake in Solabia Group
May 7, 2025
Biotechnology
Astorg has signed a definitive agreement to acquire a majority stake in Solabia Group from TA Associates, with TA reinvesting alongside Astorg. Solabia, a Paris-headquartered biotech ingredients manufacturer with 11 production sites, 8 R&D labs and over 900 employees, will partner with Astorg to accelerate international expansion (particularly in the US and Asia), advance product innovation and pursue targeted M&A.
-
BBI Solutions Acquires IBEX Technologies Inc.
April 8, 2024
Biotechnology
BBI Solutions OEM Limited has acquired IBEX Technologies Inc., a Montreal-based developer and manufacturer of high-precision enzymes and diagnostic solutions, with the transaction closing on April 8, 2024. The acquisition expands BBI's recombinant protein and enzyme capabilities to better serve in-vitro diagnostics (IVD) manufacturers and brings IBEX's staff and contract-manufacturing capabilities into BBI's global operations.
-
ICL Acquires Majority of Lavie Bio's Activities and Assets from Evogene
July 8, 2025
Biotechnology
ICL Group Ltd. has completed the acquisition of the majority of activities and assets of Lavie Bio Ltd., Evogene's ag-biologicals subsidiary, including Lavie Bio's BDD technology platform, microbial bank, pipeline and current commercial products. Evogene also transferred its MicroBoost AI tech-engine for agriculture to ICL as part of the divestiture; Lavie Bio core personnel will move to ICL while certain strategic partnerships remain with Lavie Bio.
-
Optibrium Acquires BioPharmics LLC
August 31, 2023
Software
Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.
-
Azelis Acquires Solchem Nature S.L. to Strengthen Nutraceutical Offering in Spain
April 7, 2025
Food & Beverage
Azelis has acquired 100% of Solchem Nature S.L., a Barcelona-based distributor of raw materials and premium ingredients for the nutraceutical and dietary supplements market. The deal expands Azelis's presence in Spain and adds Solchem's ~14-person team and network of over 250 customers to Azelis's EMEA nutraceutical platform.
-
Calibre Scientific Acquires MoBiTec GmbH
January 15, 2024
Biotechnology
Calibre Scientific has acquired MoBiTec GmbH, a German supplier of consumables and services for molecular and cell biology. MoBiTec will be integrated into BIOZOL Diagnostica GmbH (a Calibre subsidiary) to broaden BIOZOL's product range and strengthen the group's capabilities and sales presence in the DACH research, diagnostics, and pharmaceutical markets.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.